Changeflow GovPing Drug Safety Venlafaxine XR Recall
Urgent Enforcement Removed Final

Venlafaxine XR Recall

Favicon for recalls-rappels.canada.ca Health Canada Recalls & Safety Alerts
Filed March 10th, 2026
Detected March 10th, 2026
Email

Summary

Health Canada has issued a Type II recall for VENLAFAXINE XR 75mg capsules due to dissolution testing being out of specification. Retailers are instructed to remove the affected product from shelves. Consumers should consult a healthcare provider before discontinuing use.

What changed

Health Canada has initiated a Type II recall for VENLAFAXINE XR 75mg extended-release capsules, Lot 2505003230, manufactured by Pro-Doc Ltée. The recall is due to the drug's dissolution testing results being out of specification, indicating a potential quality issue. The depth of the recall is at the retail level.

Retailers must remove the affected product from their inventory. Consumers are advised to consult their healthcare provider before stopping the use of this medication or if they have any health concerns related to it. The company should be contacted for questions regarding the recall. Consumers are also reminded to report any adverse reactions or safety complaints to Health Canada.

What to do next

  1. Remove affected VENLAFAXINE XR 75mg capsules (Lot 2505003230) from retail inventory.
  2. Advise consumers to consult healthcare providers before discontinuing use.
  3. Report any health product-related side effects or safety complaints to Health Canada.

Source document (simplified)

Health product recall

VENLAFAXINE XR: out of specification

Brand(s)

Pro-Doc Lté

Last updated

2026-03-10

Summary

Product VENLAFAXINE XR 75mg Issue Health products - Product quality What to do

Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.

Affected products

| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot |
| --- | --- | --- | --- | --- | --- |
| VENLAFAXINE XR | VENLAFAXINE XR | DIN 02339250 | Capsule (extended release) | Venlafaxine (Venlafaxine Hydrochloride) 75mg | 2505003230 |

Issue

Dissolution is out of specification in the affected batch.

What you should do

  1. Verify if your product is affected.
  2. Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
  3. Contact the recalling firm if you have any questions about the recall.
  4. Report any health product related side effects to Health Canada.
  5. Report any other health product safety complaints to Health Canada.

Additional information

Background

Depth of recall: Retailers

Details

Original published date:

2026-03-10

Alert / recall type Health product recall Category Health products - Drugs Companies

Pro-Doc Lté.

2925 boul. Industriel,

Laval, Qc,

H7L 3W9

Published by Health Canada Audience General public Healthcare Industry Recall class Type II Recall date

2026-03-10

Identification number RA-81722

Get notified

Receive emails about new and updated recall and safety alerts.

Subscribe

Report a health or safety concern

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
Various Canadian Agencies
Filed
March 10th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Drug manufacturers Retailers Healthcare providers
Geographic scope
National (CA)

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Topics
Product Recalls Quality Control

Get Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when Health Canada Recalls & Safety Alerts publishes new changes.

Free. Unsubscribe anytime.